Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Troglitazone | Troglitazone may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Ursodeoxycholic acid | Ursodeoxycholic acid may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Cholic Acid | Cholic Acid may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Letermovir | The excretion of Letermovir can be decreased when combined with Nefazodone. |
| Valinomycin | Valinomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Olmesartan | Olmesartan may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Lenvatinib | Lenvatinib may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Cyproheptadine | The therapeutic efficacy of Nefazodone can be decreased when used in combination with Cyproheptadine. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Nefazodone is combined with Desmopressin. |
| Ioflupane I-123 | Nefazodone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Nefazodone. |
| Metyrosine | The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Nefazodone. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Nefazodone is combined with Pimozide. |
| Ramipril | Nefazodone may decrease the antihypertensive activities of Ramipril. |
| Remikiren | Nefazodone may decrease the antihypertensive activities of Remikiren. |
| Guanadrel | Nefazodone may decrease the antihypertensive activities of Guanadrel. |
| Minoxidil | Nefazodone may decrease the antihypertensive activities of Minoxidil. |
| Treprostinil | Nefazodone may decrease the antihypertensive activities of Treprostinil. |
| Trandolapril | Nefazodone may decrease the antihypertensive activities of Trandolapril. |
| Benazepril | Nefazodone may decrease the antihypertensive activities of Benazepril. |
| Candoxatril | Nefazodone may decrease the antihypertensive activities of Candoxatril. |
| Moexipril | Nefazodone may decrease the antihypertensive activities of Moexipril. |
| Nitroglycerin | Nefazodone may decrease the antihypertensive activities of Nitroglycerin. |
| Cryptenamine | Nefazodone may decrease the antihypertensive activities of Cryptenamine. |
| Candesartan cilexetil | Nefazodone may decrease the antihypertensive activities of Candesartan cilexetil. |
| Eprosartan | Nefazodone may decrease the antihypertensive activities of Eprosartan. |
| Quinapril | Nefazodone may decrease the antihypertensive activities of Quinapril. |
| Deserpidine | Nefazodone may decrease the antihypertensive activities of Deserpidine. |
| Pentolinium | Nefazodone may decrease the antihypertensive activities of Pentolinium. |
| Trimethaphan | Nefazodone may decrease the antihypertensive activities of Trimethaphan. |
| Bretylium | Nefazodone may decrease the antihypertensive activities of Bretylium. |
| Cilazapril | Nefazodone may decrease the antihypertensive activities of Cilazapril. |
| Saprisartan | Nefazodone may decrease the antihypertensive activities of Saprisartan. |
| Spirapril | Nefazodone may decrease the antihypertensive activities of Spirapril. |
| Diethylnorspermine | Nefazodone may decrease the antihypertensive activities of Diethylnorspermine. |
| Temocapril | Nefazodone may decrease the antihypertensive activities of Temocapril. |
| Rauwolfia serpentina root | Nefazodone may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Angiotensin 1-7 | Nefazodone may decrease the antihypertensive activities of Angiotensin 1-7. |
| Imidapril | Nefazodone may decrease the antihypertensive activities of Imidapril. |
| BQ-123 | Nefazodone may decrease the antihypertensive activities of BQ-123. |
| Dihydralazine | Nefazodone may decrease the antihypertensive activities of Dihydralazine. |
| Zofenopril | Nefazodone may decrease the antihypertensive activities of Zofenopril. |
| Guanoxan | Nefazodone may decrease the antihypertensive activities of Guanoxan. |
| Delapril | Nefazodone may decrease the antihypertensive activities of Delapril. |
| Vincamine | Nefazodone may decrease the antihypertensive activities of Vincamine. |
| Guanoxabenz | Nefazodone may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Nefazodone may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Nefazodone may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Nefazodone may decrease the antihypertensive activities of Cadralazine. |
| Bietaserpine | Nefazodone may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Nefazodone may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Nefazodone may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Nefazodone may decrease the antihypertensive activities of Guanoclor. |
| Candesartan | Nefazodone may decrease the antihypertensive activities of Candesartan. |
| Benazeprilat | Nefazodone may decrease the antihypertensive activities of Benazeprilat. |
| Fosinoprilat | Nefazodone may decrease the antihypertensive activities of Fosinoprilat. |
| Ramiprilat | Nefazodone may decrease the antihypertensive activities of Ramiprilat. |
| Perindoprilat | Nefazodone may decrease the antihypertensive activities of Perindoprilat. |
| Quinaprilat | Nefazodone may decrease the antihypertensive activities of Quinaprilat. |
| Enalapril | Nefazodone may decrease the antihypertensive activities of Enalapril. |
| Captopril | Nefazodone may decrease the antihypertensive activities of Captopril. |
| Irbesartan | Nefazodone may decrease the antihypertensive activities of Irbesartan. |
| Sitaxentan | Nefazodone may decrease the antihypertensive activities of Sitaxentan. |
| Azilsartan medoxomil | Nefazodone may decrease the antihypertensive activities of Azilsartan medoxomil. |
| Diazoxide | Nefazodone may decrease the antihypertensive activities of Diazoxide. |
| Buprenorphine | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Nefazodone. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Magnesium sulfate | The therapeutic efficacy of Nefazodone can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Orphenadrine | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Pramipexole | Nefazodone may increase the sedative activities of Pramipexole. |
| Ropinirole | Nefazodone may increase the sedative activities of Ropinirole. |
| Rotigotine | Nefazodone may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Nefazodone. |
| Sodium oxybate | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nefazodone. |
| Thalidomide | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Nefazodone. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Nefazodone. |
| Doxapram | The risk or severity of hypertension can be increased when Doxapram is combined with Nefazodone. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Nefazodone. |
| Omapatrilat | Nefazodone may decrease the antihypertensive activities of Omapatrilat. |
| Rescinnamine | Nefazodone may decrease the antihypertensive activities of Rescinnamine. |
| Epicaptopril | The risk or severity of hypertension can be increased when Nefazodone is combined with Epicaptopril. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when Nefazodone is combined with 1-benzylimidazole. |
| Saralasin | The risk or severity of hypertension can be increased when Nefazodone is combined with Saralasin. |
| Tyramine | The risk or severity of hypertension can be increased when Nefazodone is combined with Tyramine. |
| Atipamezole | The risk or severity of hypertension can be increased when Nefazodone is combined with Atipamezole. |
| Idazoxan | The risk or severity of hypertension can be increased when Nefazodone is combined with Idazoxan. |
| Tramazoline | The risk or severity of hypertension can be increased when Nefazodone is combined with Tramazoline. |
| Fenozolone | The risk or severity of hypertension can be increased when Nefazodone is combined with Fenozolone. |